The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance to 180 Life Sciences' ( NASDAQ: ATNF ) patent application related to treating Dupuytren's disease.
The disorder is characterized by one or more fingers to bend toward the palm of the hand due to thickening and tightening over time of the fascia — layer of tissue which lies beneath the skin in the palm.
The U.S. patent application number 17/721,106 is titled, 'Method of Treating Dupuytren’s disease Using a Pre-filled Syringe."
The application includes claims related to the use of a citrate-free formulation of 40mg in 0.4mL of adalimumab to be injected into nodules of early-stage Dupuytren's disease every 3 months for 1 year using a syringe with a 25 gauge needle, according to the company.
Adalimumab is sold as Humira by AbbVie.
"This allowance by the US Patent Office, and the expected formal patent, represent an important addition to our extensive patent estate on the use of anti-tumor necrosis factor (TNF) for the treatment of Dupuytren’s disease, which we hope in the future may be able to apply to a range of fibrotic disorders and postoperative cognitive decline," said 180 Life Sciences CEO James Woody.
In a separate release, the company noted that it was closing recruitment of people with early stage Frozen shoulder in a trial in England due to challenges faced faced in opening recruitment sites and enrolling sufficient people.
ATNF -6.23% to $2.86 premarket Feb. 23
For further details see:
180 Life Sciences to get US patent linked to treating hand disorder Dupuytren